

Table S1 Detailed search strategy according to database (14 June 2022)

PubMed search strategy (562 hits)

Years/issue searched: inception to 2022

Search date: 14 June 2022

(ground glass opaci*) AND (adenocarcinoma) AND (patholog* OR histopathog*) Filters: English

Embase search strategy (963 hits)

#1. 'ground glass opacity' OR 'ground glass' OR 'ground glass opacities'

#2. 'adenocarcinoma' OR 'pulmonary adenocarcinoma'

#3. 'pathology' OR 'pathologic' OR 'histopathology' OR 'histologic' OR 'histopathologic'

#4. #1 AND #2 AND #3 AND [english]/lim

Scopus search strategy (663 hits)

Years/issue searched: inception to 2021

Search date: 14 June 2022

((ground glass opaci*) AND (adenocarcinoma) AND (patholog* OR histopathog*) AND (LIMIT-TO (LANGUAGE, "English")))

Table S2 Eligibility criteria of included studies

| Author | Year | Country/ region | Study period | Study design | Number of Participants | Eligibility Criteria | | | | | |
|-----------|------|--------------------|--------------|----------------------------|---------------------------|-----------------------|-----------------------------------|------------------------|---|------------------------|--|
| | | | | | | Size | CT slice thickness | Synchronous lesions | Demographic factor | Pathologic criteria | Period of persistence |
| Zhu | 2022 | China | 2018–2019 | Retrospective | 653 | pGGN <30 mm | Less than 1.5 mm | | | | |
| Sun | 2022 | China | 2007–2015 | Retrospective | 69 | pGGN ≥30 mm | | | At least 5 years of follow-up | | |
| Fu | 2021 | China | 2011–2015 | Retrospective | 432 | | | Solitary | No history of malignancy | | |
| Wang | 2021 | China | 2013–2015 | Retrospective | 273 | | | | At least 5 years of follow-up | IA only included | |
| Sun | 2020 | China | 2012–2015 | Retrospective | 102 | | 1 mm | | | IA only included | |
| Li | 2020 | China | 2015–2019 | Retrospective | 90 | | 1 mm | | | AAH excluded | |
| Chen | 2019 | Taiwan | 2015–2019 | Retrospective | 59 | pGGN ≤20 mm | | Solitary | No history of malignancy | | |
| Lee | 2019 | Korea | 2012–2016 | Retrospective | 44 | pGGN <20 mm | | | | | |
| Mao | 2019 | China | 2010–2012 | Retrospective | 109 | | | | No history of malignancy | IA only included | |
| Wang | 2019 | China | 2016–2017 | Retrospective | 91 | | | | Age between 18 to 44 years, no history of malignancy | | |
| Ye | 2018 | China | 2008–2014 | Retrospective | 534 | pGGN ≤30 mm | 1 mm | | | AAH excluded | |
| Moon | 2018 | Korea | 2010–2017 | Retrospective | 106 | | | | | | |
| Li | 2018 | China | 2013–2016 | Retrospective | 167 | | | Solitary | | | |
| Sawada | 2009 | Japan | 2000–2005 | Retrospective | 63 | pGGN ≤30 mm | 1 mm from 2001 and 2 mm before | | | | |
| Yamaguchi | 2015 | Japan | 2006–2012 | Retrospective | 47 | pGGN ≤20 mm | 1 mm | | | | |
| Ichinose | 2014 | Japan | 2008–2010 | Retrospective | 114 | pGGN ≤20 mm | 1 mm slice thickness | | | | |
| Lim | 2013 | Korea | 2003–2008 | Retrospective | 46 | pGGN >10 mm | | | At least 3 years of follow-up | | persistent |
| Cho | 2013 | Korea | 2004–2009 | Retrospective | 46 | pGGN ≤30 mm | | | At least 2 years of follow-up | | |
| Eguchi | 2014 | Japan | 1998–2013 | Retrospective | 33 | | 1.25 mm | | At least 2 years of follow-up | | |
| Liang | 2015 | China | 2010–2014 | Retrospective | 74 | 5 mm ≤ pGGN ≤30 mm | | | | | Persistent |
| Kakinuma | 2016 | Japan | 2009–2011 | Multicenter prospective | 35 | pGGN ≤30 mm | Less than 1.25 mm | | | | At least 3 months of persistence |
| Fournel | 2017 | France | 2008–2014 | Retrospective | 27 | pGGN ≤30 mm | | Less than five | | | |
| Zha | 2016 | China | 2008–2014 | Retrospective | 553 | pGGN ≤30 mm | | | No history of malignancy | | |
| Kitami | 2016 | Japan | 2001–2014 | Retrospective | 78 | pGGN ≤30 mm | | | | | At least 3 months of persistence |

AAH, Atypical adenomatous hyperplasia; CT, computed tomography; IA, invasive adenocarcinoma; pGGN, pure ground glass nodule.




Figure S1 Forest plot of meta-analysis to estimate the proportion of atypical adenomatous hyperplasia among resected pure ground glass pulmonary lesions.




Figure S2 Forest plot of meta-analysis to estimate the proportion of adenocarcinoma in situ among resected pure ground glass pulmonary lesions.




Figure S3 Forest plot of meta-analysis to estimate the proportion of minimally invasive adenocarcinoma among resected pure ground glass pulmonary lesions.